SANIONA AB (PUBL) (30S) - Total Liabilities
Based on the latest financial reports, SANIONA AB (PUBL) (30S) has total liabilities worth €44.58 Million EUR (≈ $52.12 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore SANIONA AB (PUBL) equity growth rate to track the company's year-over-year net asset growth rate.
SANIONA AB (PUBL) - Total Liabilities Trend (2021–2025)
This chart illustrates how SANIONA AB (PUBL)'s total liabilities have evolved over time, based on quarterly financial data. See 30S free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
SANIONA AB (PUBL) Competitors by Total Liabilities
The table below lists competitors of SANIONA AB (PUBL) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Korea Air Svc
KO:005430
|
Korea | ₩143.98 Billion |
|
Duos Technologies Group Inc
NASDAQ:DUOT
|
USA | $20.29 Million |
|
First Steamship Co Ltd
TW:2601
|
Taiwan | NT$20.68 Billion |
|
Curexo Inc
KQ:060280
|
Korea | ₩9.36 Billion |
|
TrueBlue Inc
NYSE:TBI
|
USA | $364.59 Million |
|
JVM Co. Ltd
KQ:054950
|
Korea | ₩92.00 Billion |
|
Barings Participation Investors (the Trust)
NYSE:MPV
|
USA | $44.52 Million |
|
Goodway Machine Corp
TW:1583
|
Taiwan | NT$8.02 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down SANIONA AB (PUBL)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see SANIONA AB (PUBL) market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.48 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SANIONA AB (PUBL)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SANIONA AB (PUBL) (2021–2025)
The table below shows the annual total liabilities of SANIONA AB (PUBL) from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €44.58 Million ≈ $52.12 Million |
-58.69% |
| 2024-12-31 | €107.92 Million ≈ $126.16 Million |
+25.36% |
| 2023-12-31 | €86.08 Million ≈ $100.64 Million |
-14.76% |
| 2022-12-31 | €100.99 Million ≈ $118.07 Million |
-36.18% |
| 2021-12-31 | €158.25 Million ≈ $185.01 Million |
-- |
About SANIONA AB (PUBL)
Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company's product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical t… Read more